Investments
33Portfolio Exits
2Funds
1
Want to inform investors similar to LYZZ Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest LYZZ Capital News
Jun 24, 2022
(Yicai Global) June 24 -- Mojia Biotech, a Chinese bio-manufacturing company, has raised USD80 million in its latest financing round led by Singaporean sovereign wealth fund Temasek Holdings. Private equity investor Lyzz Capital, which focuses on the biotech sector, and existing shareholders Bits x Bites and Asia Green Fund were among others joining the Series B fundraiser, the Shanghai-based company said in a statement yesterday. The proceeds will be used to speed up commercialization of its Viridimin brand of animal-feed additives, scale up the manufacturing capacity of the Aliphane series of bio-based materials, advance the firm’s product pipeline, and expand its global research and development capabilities, Mojia Biotech added. “Sustainable ingredient manufacturing is a pillar for a thriving green economy,” said Joseph Zhou, managing partner of Bits x Bites. “And with the recent delays and shortages in the global supply chain highlighting the importance of reducing reliance on raw material imports, we see huge potential for Mojia Biotech to apply its technology across different chemical ingredients, and to become a leader for the next-generation green chemical production.” The Viridimin series of vitamin B5 products is expected to go into mass production this month. Compared with traditional production processes, those for Viridimin products use biological manufacturing technologies to save energy and cut emissions, Mojia Biotech pointed out. The Aliphane series of biopolymer products, the firm’s second to be commercialized, is highly versatile and has great potential in coating and adhesive applications, the company said. Editor: Futura Costaglione
LYZZ Capital Investments
33 Investments
LYZZ Capital has made 33 investments. Their latest investment was in Minovia Pharmaceutical as part of their Series A on July 7, 2022.

LYZZ Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/21/2022 | Series A | Minovia Pharmaceutical | Yes | 1 | ||
7/7/2022 | Seed VC | Yiteng Medical | Yes | 1 | ||
6/23/2022 | Series B | Mojia Bio | $80M | Yes | 2 | |
4/29/2022 | Series A | |||||
4/22/2022 | Series A |
Date | 7/21/2022 | 7/7/2022 | 6/23/2022 | 4/29/2022 | 4/22/2022 |
---|---|---|---|---|---|
Round | Series A | Seed VC | Series B | Series A | Series A |
Company | Minovia Pharmaceutical | Yiteng Medical | Mojia Bio | ||
Amount | $80M | ||||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 1 | 2 |
LYZZ Capital Portfolio Exits
2 Portfolio Exits
LYZZ Capital has 2 portfolio exits. Their latest portfolio exit was Microtech Medical on October 19, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
10/19/2021 | IPO | Public | 5 | ||
Date | 10/19/2021 | |
---|---|---|
Exit | IPO | |
Companies | ||
Valuation | ||
Acquirer | Public | |
Sources | 5 |
LYZZ Capital Fund History
1 Fund History
LYZZ Capital has 1 fund, including Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund | Multi-Stage Venture Capital | Open | 1 |
Closing Date | |
---|---|
Fund | Jiangsu Jiequan Lyzz Healthcare Venture Capital Fund |
Fund Type | Multi-Stage Venture Capital |
Status | Open |
Amount | |
Sources | 1 |
LYZZ Capital Team
1 Team Member
LYZZ Capital has 1 team member, including current Managing Partner, Kevin Li.
Name | Work History | Title | Status |
---|---|---|---|
Kevin Li | Toucan Capital | Managing Partner | Current |
Name | Kevin Li |
---|---|
Work History | Toucan Capital |
Title | Managing Partner |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.